Innovating Drug Discovery

Pioneering Solutions for a Healthier Tomorrow

Leading the Way in Drug Innovation
Shaping the Future of Medicine, One Discovery at a Time

Services

Target Identification

Target Identification

Utilizing advanced technologies to identify molecular targets that are crucial in disease pathology, ensuring early and precise intervention.

Compound Screening

Compound Screening

High-throughput screening of chemical compounds to rapidly identify potential drug candidates with therapeutic benefits.

Preclinical Testing

Preclinical Testing

Robust preclinical testing protocols to evaluate drug efficacy and safety, paving the way for successful clinical trials.

About Us
The foundation Stichting Eigen Regie, (kvk) 70567573 was established on januari 8 th 2018. It's core activities were wound management in elderly care.The development of anti-infectives gained momentum during the Covid pandemic.  As a start-up, BeneluxBio does its own in-house research and has licensed compounds from Liberpharma. Liberpharma became in 2022 the trading name of the Stichting Eigen Regie. With a commitment to innovation and patient care, we aim to develop new medicines that address infectious diseases,epilepsy in cooperation with the University of Maastricht, and multiple myeloma ( via molecular glues).Many compounds  were designed and developed under a program of the NCI.Director is mr. J.H.A. Cornelesen
We are gratefull to our former director mr. R.G. Dassen(Itteren,Netherlands)for his relentless commitment to the Stichting Eigen Regie

Collaborations,Pipeline,Patents

 We turn our projects into products by closing collaborative agreements with Universities,Hospitals, Dutch SME's(Mkb ),Flemish Institutions and Universities located in North-Holland, South-Holland,Brabant,Limburg, Gelderland and Flanders 

 30 investigational new molecular entities are registered at iDEPOT for chemical synthesis and testing in bioassays We have a location in Flanders that supports our operations in the Flemish region ( VLAIO) 

 BeneluxBio is diversifying its portfolio and executing on its strategy which is broadly based on two strategic pillars: antibiotics and immuno-oncology. We use proprietary lead compounds. We are a pharmaceutical research and development company and not a services company. 

 European Innovation programme South Netherlands 

 With support from the European Union Medegefinancierd door de Europese Unie 

 Discovered, developed and produced in the Benelux 

Contact

  • Maastricht, Netherlands
  • Hondertmarck 47 C,6211 MB